NovaBay Pharmaceuticals 

$1.1150
93
+$0.09+9.31% Today

Statistics

Day High
1.15
Day Low
1.04
52W High
95.8
52W Low
1.02
Volume
1,099,272
Avg. Volume
-
Mkt Cap
140.5M
P/E Ratio
-
Dividend Yield
392.16%
Dividend
4.37

Upcoming

Dividends

392.16%Dividend Yield
Sep 25
$4.00
Sep 25
$4.00
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

6AugExpected
Q2 2024
Q3 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Next
-1.37
-0.98
-0.6
-0.21
Expected EPS
-0.55
Actual EPS
N/A

Financials

-88.01%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
19.56MRevenue
-17.22MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow NBY. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Ocular Therapeutix
OCUL
Mkt Cap1.81B
Ocular Therapeutix focuses on developing treatments for eye diseases, directly competing with Novabay's eye care products.
National Vision
EYE
Mkt Cap1.29B
National Vision Holdings operates in the eye care market, offering products that can be seen as alternatives to Novabay's offerings.
Alcon
ALC
Mkt Cap32.6B
Alcon specializes in eye care products, including surgical, vision care, and ophthalmic pharmaceuticals, competing across several of Novabay's key areas.
Johnson & Johnson
JNJ
Mkt Cap579.83B
Johnson & Johnson, through its Vision Care division, competes in the eye health sector, offering products that rival Novabay's.
Pfizer
PFE
Mkt Cap149.38B
Pfizer has a broad range of healthcare products, including treatments for eye conditions that compete with Novabay's pharmaceuticals.
Novartis
NVS
Mkt Cap292.07B
Novartis offers a wide range of healthcare products, including ophthalmic solutions that compete with Novabay's eye care products.
Bausch Health Companies
BHC
Mkt Cap1.89B
Bausch Health Companies, through its eye health division, directly competes with Novabay in the ophthalmology and optometry markets.
Regeneron Pharmaceuticals
REGN
Mkt Cap64.18B
Regeneron Pharmaceuticals is involved in developing treatments for eye diseases, offering products that compete with Novabay's portfolio.
Abbvie
ABBV
Mkt Cap402.35B
AbbVie, having acquired Allergan, competes in the eye care sector with a portfolio that includes treatments for various eye conditions, challenging Novabay's market share.

About

NovaBay Pharmaceuticals, Inc. (NBY) is a pharmaceutical company that specializes in developing and globally distributing products for eyecare and dermatology. Its product portfolio includes Avenova, an advanced solution designed for cleaning the delicate skin around the eye, such as the eyelids, by removing foreign substances, microorganisms, and debris. The company also offers wound management solutions under its NeutroPhase and PhaseOne brands. Furthermore, NovaBay provides a variety of dermatological treatments through its DERMAdoctor brand, addressing diverse skin concerns. These include conditions like keratosis pilaris, rosacea, and eczema, as well as anti-aging formulations, SPF protection, remedies for hyperhidrosis (excessive sweating), solutions for unwanted hair, and acne treatments. The company distributes its products through a multi-channel approach, utilizing traditional retailers, digital beauty platforms, various distributors, and its own online sales channels. Founded in 2000, the company was initially known as NovaCal Pharmaceuticals, Inc., before officially adopting the name NovaBay Pharmaceuticals, Inc. in February 2007. Its corporate headquarters are located in Emeryville, California.
Show more...
CEO
Mr. Michael Kazley
Employees
13
Country
United States
ISIN
US66987P2011

Listings

0 Comments

Share your thoughts

FAQ

What is NovaBay Pharmaceuticals stock price today?
The current price of NBY is $1.12 USD — it has increased by +9.31% in the past 24 hours. Watch NovaBay Pharmaceuticals stock price performance more closely on the chart.
What is NovaBay Pharmaceuticals stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange NovaBay Pharmaceuticals stocks are traded under the ticker NBY.
Is NovaBay Pharmaceuticals stock price growing?
NBY stock has fallen by -4.74% compared to the previous week, the month change is a -33.43% fall, over the last year NovaBay Pharmaceuticals has showed a -63.17% decrease.
What is NovaBay Pharmaceuticals market cap?
Today NovaBay Pharmaceuticals has the market capitalization of 140.5M
When is the next NovaBay Pharmaceuticals earnings date?
NovaBay Pharmaceuticals is going to release the next earnings report on August 06, 2026.
What is NovaBay Pharmaceuticals revenue for the last year?
NovaBay Pharmaceuticals revenue for the last year amounts to 19.56M USD.
What is NovaBay Pharmaceuticals net income for the last year?
NBY net income for the last year is -17.22M USD.
Does NovaBay Pharmaceuticals pay dividends?
Yes, NBY dividends are paid en. The last dividend per share was 4 USD. As of today, Dividend Yield (FWD)% is 392.16%.
How many employees does NovaBay Pharmaceuticals have?
As of June 15, 2026, the company has 13 employees.
In which sector is NovaBay Pharmaceuticals located?
NovaBay Pharmaceuticals operates in the Health & Wellness sector.
When did NovaBay Pharmaceuticals complete a stock split?
The last stock split for NovaBay Pharmaceuticals was on February 23, 2026 with a ratio of 1:5.
Where is NovaBay Pharmaceuticals headquartered?
NovaBay Pharmaceuticals is headquartered in Emeryville, United States.